相关实验视频

Updated: Sep 16, 2025

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

在非小细胞肺癌中的亚克隆免疫逃避

Krijn K Dijkstra¹, Roberto Vendramin², Despoina Karagianni³

¹Department of Molecular Oncology and Immunology, the Netherlands Cancer Institute, Amsterdam, the Netherlands; Cancer Evolution and Genome Instability Laboratory, The Francis Crick Institute, London, UK; Cancer Research UK Lung Cancer Centre of Excellence, University College London Cancer Institute, University College London, London, UK; Oncode Institute, Utrecht, the Netherlands.

|July 4, 2025

概括

由于瘤异质性,癌症免疫疗法经常失败. 这项研究开发了一个平台来分析不同的癌细胞克隆如何逃避免疫攻击,揭示亚克隆进化驱动免疫逃脱.

科学领域:

在瘤学瘤学.
免疫学免疫学免疫学
癌症演化演化癌症演化

背景情况:

免疫疗法是癌症治疗的基石,但完全的反应很少见.
瘤是由基因多样化的亚克隆组成的,但它们在免疫逃脱中的作用尚不清楚.
之前的研究面临着从人类瘤中分离和研究个体癌症亚克隆的挑战.

研究的目的:

为了研究瘤亚克隆异质性对免疫逃生的影响.
开发一种新的平台,以单细胞分辨率分析亚克隆性免疫逃避.
了解免疫逃避癌症克隆的进化动态.

主要方法:

来自三个肺癌患者的多个区域的确立的患者衍生器官系.
从这些有机体中分离和繁殖了81个不同的克隆子线.
与瘤透性淋巴细胞 (TIL) 和自然杀手细胞 (NK) 共同培养的分离癌症亚克隆.

主要成果:

在所有三名研究患者中,已证明癌症内在和亚克隆性免疫逃脱.
鉴定出具有独特进化历史的免疫逃避子克隆的遗传独特血统.
展示了从同一瘤中分离免疫逃避和非逃避子克隆的能力.

结论:

亚克隆瘤进化直接影响癌症逃避免疫监测的能力.
了解亚克隆动态对于提高免疫疗法的疗效至关重要.
开发的有机T细胞共同培养平台使得亚克隆免疫逃逸的功能分析成为可能.

关键词:

一个T细胞细胞.癌症的演化癌症的演化免疫系统的逃脱是免疫逃脱.免疫逃避免疫逃避免疫监测免疫监测免疫监测免疫疗法免疫疗法内部异质性的异质性非小细胞肺癌的肺癌.有机生物有机物瘤的演变瘤的演变瘤免疫学瘤免疫学

更多相关视频

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Author Spotlight: Establishing a Murine Non-Small Cell Lung Cancer Model for Developing Nanoformulations of Anticancer Drugs

Published on: May 10, 2024

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Experimental Metastasis and CTL Adoptive Transfer Immunotherapy Mouse Model

Published on: November 26, 2010

相关概念视频

Adaptive Mechanisms in Cancer Cells

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...

Cancer Stem Cells and Tumor Maintenance

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...

Metastasis

Metastasis

Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...